Tissue Regenix pig tissue patch approved
EUROPEAN regulators have approved a new medical device made from pig tissue in a major step forward for a Yorkshire firm.
Tissue Regenix has secured European CE marking for its patch that will be used to repair damaged blood vessels, opening the way for its use across the continent.
The York-based firm has developed a new technology, known as dCELL, that removes cells and other components from human and animal tissues in a way that means they can be implanted in people without the need for anti-rejection drugs.
John Samuel, executive chairman at Tissue Regenix, said: “The granting of a European CE mark for the dCELL Vascular Patch, our first product approved for launch, is an historic moment for Tissue Regenix.
“As well as providing access to some of the world’s largest medical devices markets, today’s announcement acts as a validation of our dCELL technology platform.”
The company, which joined the AIM market in June through a reverse takeover of Oxeco, will manufacture the patch at its York facility and is continuing to pursue approval for the device with US regulators.
It is also working on a second product using the same technology, known as the dCELL Meniscus, which could be used to repair damaged knee tissue.
Tissue Regenix was launched as a spinout company from the University of Leeds in 2006.
